The B2MIC method is an in vitro diagnostic test for the quantitative measurement of ß₂microglobulin in human serum, heparinized plasma, EDTA plasma and urine using the B2MIC Flex® reagent cartridge on the Dimension Vista® Systems. Measurement of ß 2 -microglobulin aids in the diagnosis of active rheumatoid arthritis and kidney disease.

PROT1 CAL is an in vitro diagnostic product for the calibration of the Dimension Vista® Systems for: αγ-Acid Glycoprotein (A1AG), α1-Antitrypsin (A1AT), a2-macroglobulin (A2MAC), IS2-Microglobulin (B2MIC, B2MU**), C3 Complement (C3), C4 Complement (C4), Ceruloplasmin (CER), Haptoglobin (HAPT),Hemopexin (HPX), Homocysteine (HCYS), Immunoglobulin A (IGA), Immunoglobulin E (IGE), Immunoglobulin G (IGG, IGG-C*, ICC-U**), Immunoglobulin G subclass 1(IGG1), Immunoglobulin G subclass 2 (IGG2), Immunoglobulin G subclass 3 (IGG3), Immunoglobulin G subclass 4 (IGG4), Immunoglobulin M (IGM), Prealbumin (PREALB), Retinol Binding Protein (RBP), soluble Transferrin Receptor (STFR), Transferrin (TRF)
*For cerebrospinal fluid
** For urine

PROT1 CON L is an assayed, low level, intralaboratory quality control for assessment of precision and analytical bias on the Dimension Vista® Systems in the quantitative determination of: α-Acid Glycoprotein (A1AG), α-- Antitrypsin (A1AT), a2 -- Macroglobulin (A2MAC), ß2-Microglobulin (B2MIC-U *), C3 Complement (C3), C4 Complement (C4), Ceruloplasmin (CER), Haptoglobin (HAPT), Hemopexin (HPX), Homocysteine (HCYS), Immunoglobulin A (IGA), Immunoglobulin E (IGE), Immunoglobulin G (IGG),Immunoglobulin G subclass 1 (IGG1), Immunoglobulin G subclass 2 (IGG2), Immunoglobulin G subclass 3 (IGG3), Immunoglobulin G subclass 4 (IGG4), Immunodlobulin M (IGM), Prealbumin (PREALB), Retinol Binding Protein (RBP), specialty Albumin (sALB), soluble Transferrin Receptor (STFR) and Transferrin (TRF).
*For serum and plasma
** For Urine

PROT1 CON M is an assayed, mid-level, intralaboratory quality controls for assessment of precision and analytical bias on the Dimension Vista® System in the quantitative determination of: : α -- Acid Glycoprotein (A1AG), α -- Antitrypsin (A1AT), α 2 -- Macroglobulin (A2MAC), ß2-Microglobulin (B2MIC*,B2MIC-U**), C3 Complement (C3), C4 Complement (C4), Ceruloplasmin (CER), Haptoglobin (HAPT), Hemopexin (HPX), Homocysteine (HCYS), Immunoglobulin A (IGA), Immunoglobulin E (IGE), Immunoglobulin G (IGG), Immunoglobulin G subclass 1 (IGG1), lmmunoqlobulin G subclass 2 (IGG2), Immunoglobulin G subclass 3 (IGG3), Immunoglobulin G subclass 4 (IGG4), Immunoglobulin M (IGM), Prealbumin (PREALB), Retinol Binding Protein (RBP), specialty Albumin (sALB*), soluble Transferrin Receptor (STFR), and Transferrin (TRF),
*For serum and plasma
** For urine

Device Description

Dimension Vista® B2MIC Flex® reagent cartridge: Proteins contained in human body fluids form immune complexes in an immunochemical reaction with specific antibodies. These complexes scatter a beam of light passed through the sample. The intensity of the scattered light is proportional to the concentration of the respective protein in the sample. The result is evaluated by comparison with a standard of known concentration.

Dimension Vista® Protein 1 Calibrator: Protein 1 Calibrator is a multi-analyte, liquid human serum based product containing: a+acid glycoprotein, a1 -antitrypsin, a1-macroglobulin, 132 -microglobulin, C3 complement, C4 complement, ceruloplasmin, haptoglobin, hemopexin, immunoglobulin A, immunoglobulin E, immunoglobulin G, immunoglobulin G subclass 1, immunoglobulin G subclass 2, immunoglobulin G subclass 3, immunodlobulin G subclass 4, immunoglobulin M, prealbumin, retinol binding protein, homocysteine, soluble transferrin receptor and transferrin.

Dimension Vista® Protein 1 Control L: Protein 1 Control L is a multi-analyte, low level liquid human serum based product containing : q-acid glycoprotein, α-- antitrypsin, α 2-macroglobulin, ß-microglobulin, C3 complement, C4 complement,ceruloplasmin, haptoglobin, hemopexin,immunoglobulin E, immunoglobulin A, immunoglobulin G, immunoqlobulin G Subclass , immunoglobulin G subclass 2, immunoglobulin G subclass 3, immunoglobulin G subclass 4, immunoglobulin M, prealburnin, retinol binding protein, homocysteine, soluble transferrin receptor and transferrin

Dimension Vista® Protein 1 Control M: Protein 1 Control M is a multi-analyte, mid level, liquid human serum based product containing: Q -- acid glycoprotein, a -- antitrypsin, as -macroglobulin, 13-microglobulin, C3 complement, C4 complement, ceruloplasmin, haptoglobin, hemopexin, immunoglobulin A, immunoglobulin E, immunoglobulin G, immunoglobulin G subclass 1, immunoglobulin G subclass 2, immunoglobulin G subclass 3. immunodobulin G subclass 4. immunoglobulin M, prealbumin, retinol binding protein, homocysteine, soluble transferrin receptor, and transferrin.

AI/ML Overview

Here's an analysis of the provided text regarding the acceptance criteria and study for the Dimension Vista® B2MIC Flex® reagent cartridge:

The document describes a 510(k) submission for an in vitro diagnostic device, primarily focusing on showing substantial equivalence to a legally marketed predicate device. This type of submission usually doesn't involve the same kind of acceptance criteria as AI/ML-based medical devices for image interpretation or diagnosis. Instead, the "acceptance criteria" here are typically performance characteristics that demonstrate the new device is comparable to the predicate.

1. Table of Acceptance Criteria and Reported Device Performance

For this type of device (a reagent cartridge for quantitative measurement), the key performance characteristic evaluated is method comparison against a predicate device. The performance is assessed using regression analysis.

Acceptance Criteria (Implied)	Reported Device Performance (B2MIC Flex® vs. BN ProSpec®)
Correlation Coefficient	0.988
Slope	0.952
Intercept	-0.0008 mg/dL (-0.008 mg/L)

Note: The acceptance criteria are "implied" because in a 510(k) for a quantitative assay, the goal is to show acceptable agreement with a predicate. While explicit numerical acceptance thresholds aren't stated here (e.g., "slope must be between 0.9 and 1.1"), the high correlation coefficient (0.988) and a slope close to 1 with an intercept close to 0 demonstrate substantial equivalence and acceptable performance.

2. Sample Size Used for the Test Set and Data Provenance

Sample Size for Test Set: 82 urine samples
Data Provenance: The document does not explicitly state the country of origin. It is a retrospective study as it's a "Method Comparison Study" where samples are analyzed by both the new device and a predicate device. The samples are collected and then tested on both systems.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts

For this type of in vitro diagnostic device measuring a biomarker concentration, the "ground truth" isn't established by human experts in the same way it would be for an imaging AI. Instead, the "ground truth" is typically the result obtained from the legally marketed predicate device, which is considered the reference method for comparison.

Number of "Experts": Not applicable in the traditional sense. The predicate device (Siemens N Latex to Human ß₂-microglobulin on the BN ProSpec® System) served as the reference.
Qualifications of "Experts": Not applicable. The predicate device itself is the standard against which the new device is compared.

4. Adjudication Method for the Test Set

Not applicable. As described above, the comparison is against the predicate device's results; there is no human adjudication process involved for establishing ground truth for individual samples.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

Not applicable. This is an in vitro diagnostic (IVD) device for quantitative measurement, not an AI/ML device for image interpretation or human assistance. Therefore, MRMC studies and "human reader improvement with/without AI" are not relevant to this submission.

6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) was done

Yes, in a sense. The described "Method Comparison Study" is a standalone evaluation of the device's analytical performance (i.e., its ability to accurately measure ß₂-microglobulin concentrations) against a reference method. It assesses the device's output numerically without direct human interpretation within the measurement process.

7. The Type of Ground Truth Used

The ground truth used for the method comparison study was the quantified measurement of ß₂-microglobulin obtained from the legally marketed predicate device (Siemens N Latex to Human ß₂-microglobulin on the BN ProSpec® System). This is a form of "reference method" ground truth.

8. The Sample Size for the Training Set

Not applicable. This is a traditional IVD device, not an AI/ML algorithm that undergoes a training phase with a specific training set. The device's performance is based on its chemical reactions and optical detection, not on learning from a dataset.

9. How the Ground Truth for the Training Set was Established

Not applicable. As this is not an AI/ML device, there is no "training set" or ground truth establishment for such a set.

Summary

{0}------------------------------------------------

Ko 83463

MAR. 1, 2009

510(k) Summary for

Dimension Vista® B2MIC Flex® reagent cartridge

Dimension Vista® Protein 1 Calibrator

Dimension Vista® Protein 1 Control L and M

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

Manufacturer's Name, Address, Telephone, and Contact Person, Date of Preparation:

Manufacturer: Siemens Healthcare Diagnostics Products

Emil-von-Behring Str. 76

35041 Marburg, Germany

Contact Information: Siemens Healthcare Diagnostics.

500 GBC Drive, M/S 514

Newark, Delaware 19702

Attn: Anna Marie Kathleen Ennis

Tel: 302-632-9352

Fax: 302-631-6299

Preparation date: February 4, 2009

Device Name:

Dimension Vista® B2MIC Flex® reagent cartridge

Dimension Vista® PROT 1 CAL

Dimension Vista® PROT 1 CON L and M

Classification: Class II; Class II; Class I

Product Code: JZG, JIX, JJY

Panel: Immunology (82) and Clinical Chemistry (75)

3. Identification of the Legally Marketed Devices:

Siemens N Latex ß2- microglobulin - K002731

{1}------------------------------------------------

N Protein Standard SL - K052788

N/T Protein Controls SL - K052788

4. Device Descriptions:

Dimension Vista® B2MIC Flex® reagent cartridge

Proteins contained in human body fluids form immune complexes in an immunochemical reaction with specific antibodies. These complexes scatter a beam of light passed through the sample. The intensity of the scattered light is proportional to the concentration of the respective protein in the sample. The result is evaluated by comparison with a standard of known concentration.

Dimension Vista® Protein 1 Calibrator

Protein 1 Calibrator is a multi-analyte, liquid human serum based product containing: a+acid glycoprotein, a1 -antitrypsin, a1-macroglobulin, 132 -microglobulin, C3 complement, C4 complement, ceruloplasmin, haptoglobin, hemopexin, immunoglobulin A, immunoglobulin E, immunoglobulin G, immunoglobulin G subclass 1, immunoglobulin G subclass 2, immunoglobulin G subclass 3, immunodlobulin G subclass 4, immunoglobulin M, prealbumin, retinol binding protein, homocysteine, soluble transferrin receptor and transferrin.

Dimension Vista® Protein 1 Control L

Protein 1 Control L is a multi-analyte, low level liquid human serum based product containing :

q-acid glycoprotein, α-- antitrypsin, α 2-macroglobulin, ß-microglobulin, C3 complement, C4 complement,ceruloplasmin, haptoglobin, hemopexin,immunoglobulin E, immunoglobulin A, immunoglobulin G, immunoqlobulin G Subclass , immunoglobulin G subclass 2, immunoglobulin G subclass 3, immunoglobulin G subclass 4, immunoglobulin M, prealburnin, retinol binding protein, homocysteine, soluble transferrin receptor and transferrin

Dimension Vista® Protein 1 Control M

Protein 1 Control M is a multi-analyte, mid level, liquid human serum based product containing: Q -- acid glycoprotein, a -- antitrypsin, as -macroglobulin, 13-microglobulin, C3 complement, C4 complement, ceruloplasmin, haptoglobin, hemopexin, immunoglobulin A, immunoglobulin E, immunoglobulin G, immunoglobulin G subclass 1, immunoglobulin G subclass 2, immunoglobulin G subclass 3. immunodobulin G subclass 4. immunoglobulin M, prealbumin, retinol binding protein, homocysteine, soluble transferrin receptor, and transferrin.

5. Device Intended Uses

Dimension Vista® B2MIC Flex® reagent cartridge:

The B2MU method is an in vitro diagnostic test for the quantitative measurement of ß₂microglobulin in human serum, heparinized plasma, EDTA plasma and urine using the B2MIC Flex® reagent cartridge on the Dimension Vista® Systems. Measurement of ß 2 -microglobulin aids in the diagnosis of active rheumatoid arthritis and kidney disease.

Dimension Vista® PROT 1 CAL:

{2}------------------------------------------------

*For cerebrospinal fluid

** For urine

Dimension Vista® Protein 1 Control L

*For serum and plasma

** For Urine

Dimension Vista® Protein 1 Control M

*For serum and plasma

** For urine

6. Medical device to which equivalence is claimed and comparison information:

The Dimension Vista® B2MJC Flex® reagent cartridge, Dimension Vista® PROT 1 CAL and Dimension Vista® PROT 1 CON L and M, are substantially equivalent to the Siemens N Latex ßz-microglobulin assay (K002731), N/T Protein Standard SL (K052788) and N Protein Controls SL (K052788). The Dimension Vista® B2MIC assay, like Siemens N Latex (1 2-microglobulin assay is an in vitro diagnostic test for the quantitative measurement of ß2 -microglobulin in human serum, plasma and urine.

7. Device Performance Characteristics:

{3}------------------------------------------------

Method Comparison Study

The Dimension Vista® B2MU assay was compared to the N Latex to Human ß ₂-microglobulin on the BN ProSpec® System by evaluating urine samples with concentrations ranging from 0.022 – 0.553 mg/dL (0.223 – 5.53mg/L). Regression analysis of these results yielded the following equation:

ComparativeMethod	Slope	Interceptmg/dL (mg/L)	CorrelationCoefficient	n
β₂-microglobulinon BN Prospec®	0.952	-0.0008 (-0.008)	0.988	82

{4}------------------------------------------------

Image /page/4/Picture/0 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle with three stripes forming its wing and body. The eagle faces to the right. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular fashion around the eagle.

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

Seimens Healthcare Diagnostics Inc. c/o Ms. Anna Marie Kathleen Ennis Senior Regulatory Affairs and Compliance Specialist 500 GBC Drive P.O. Box 601 Newark, DE 19714-6101 US

MAR 1 3 2009

Re: K083463

Trade/Device Name: Dimension Vista® B2MIC Flex® reagent cartridge Dimension Vista® Protein 1 Calibrator Dimension Vista® Protein 1 Control L

Dimension Vista® Protein 1 Control M

Regulation Number: 21 CFR 866.5630 Regulation Name: Beta-2-microglobulin immunological test system Regulatory Class: Class II Product Code: JZG, JIX, JJY Dated: February 4, 2009 Received: February 5, 2009

Dear Ms. Ennis,

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must

{5}------------------------------------------------

Page 2 - Ms. Anna Marie Kathleen Ennis

comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at 240-276-0450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely vours.

' mchen

Maria M. Chan, Ph.D. Director Division of Immunology and Hematology Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health

Enclosure

{6}------------------------------------------------

Indication for Use

510(k) Number (if known): KO83463

Device Name: Dimension Vista® B2MIC Flex Reagent Cartridge

Indication for Use:

The B2MIC method is an in vitro diagnostic test for the quantitative measurement of ß2-microglobulin in human serum, heparinized plasma, EDTA plasma and urine on the Dimension Vista® System. Measurements of beta-2-microglobulin, aid in the diagnosis of active rheumatoid arthritis and kidney disease.

Prescription Use _ X

And/Or

Over the Counter Use

(21 CFR Part 801

(21 CFR Part 801 Subpart D) Subpart C)

(Please Do Not WRITE BELOW THIS LINE; CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OMD)---

Maria In Chain

Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety

510(k) Kofs463

Page 1 of 1

{7}------------------------------------------------

Indications for Use

510(k) Number (if known): Kod3 4 63

Dimension Vista® PROT 1 CON L Device Name:

Indications For Use:

PROT1 CON L is an assayed, low-level, intralaboratory quality control for the assessment of precision and analytical bias on the Dimension Vista® System in the quantitative determination of:

α₁-Acid Glycoprotein (A1AG)	Immunoglobulin G (IGG)
α₁-Antitrypsin (A1AT)	Immunoglobulin G Subclass 1 (IGG1)
α₂-Macroglobulin (A2MAC)	Immunoglobulin G Subclass 2 (IGG2)
β₂-Microglobulin (B2MIC, B2MU**)	Immunoglobulin G Subclass 3 (IGG3)
C3 Complement (C3)	Immunoglobulin G Subclass 4 (IGG4)
C4 Complement (C4)	Immunoglobulin M (IGM)
Ceruloplasmin (CER)	Prealbumin (PREALB)
Haptoglobin (HAPT)	Retinol binding Protein (RBP)
Hemopexin (HPX)	soluble Transferrin Receptor (STFR)
Homocysteine (HCYS)	specialty Albumin (sALB*)
Immunoglobulin A (IGA)	Transferrin (TRF)
Immunoglobulin E (IGE)

For serum and plasma

** For urine

Prescription Use _ × (Per 21 CFR 801 Subpart D) Over-The-Counter-Use_ (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE -- CONTINUE ON ANOTHER PAGE IF NEEDED)

AND/OR

Concurrence of CDRH, Office of Device Evaluation

Page 1 of

Maria M'Chen.

Division Slan-

Office of In Vitro Diagnostic Device Evaluation and Safety

5100

{8}------------------------------------------------

Indications for Use

510(k) Number (if known): Ko 8 346 3

Device Name:

For Urine

Dimension Vista® PROT 1 CAL

Indications For Use:

Dimension Vista® PROT 1 CAL:

PROT1 CAL is an in vitro diagnostic product for the calibration of the Dimension Vista® System for:

a1-Acid Glycoprotein (A1AG) a1-Antitrypsin (A1AT) a2- Macroglobulin (A2MAC) B2-Microglobulin (B2MIC, B2MU**) C3 Complement (C3) C4 Complement (C4) Ceruloplasmin (CER) Haptoglobin (HAPT) Hemopexin (HPX) Homocysteine (HCYS) Immunoglobulin A (IGA) * For cerebrospinal fluid (CSF)

Immunoglobulin E (IGE) Immunoqlobulin G {IGG, IGG-C*, IGG-U**) Immunoglobulin G Subclass 1 (IGG1) Immunoglobulin G Subclass 2 (IGG2) Immunoglobulin G Subclass 3 (IGG3) Immunoglobulin G Subclass 4 (IGG4) lmmunoglobulin M (IGM) Prealbumin (PREALB) Retinol binding Protein (RBP) soluble Transferrin Receptor (STFR) Transferrin (TRF)

Prescription Use × (Per 21 CFR 801 Subpart D)

Over-The-Counter-Use AND/OR (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation

. Page 1 of

ia m chan

Division Sign-Off

Office of In Vitro Diagnostic Device Evaluation and Safety

510(k) K083463

{9}------------------------------------------------

Indications for Use

510(k) Number (if known): Ko83463

Dimension Vista® PROT 1 CON M Device Name:

Indications For Use:

PROT1 CON M is an assayed, mid-level, intralaboratory quality control for the assessment of precision and analytical bias on the Dimension Vista® System in the quantitative determination of:

a₁-Acid Glycoprotein (A1AG)	Immunoglobulin G (IGG)
a₁-Antitrypsin (A1AT)	Immunoglobulin G Subclass 1 (IGG1)
α₂-Macroglobulin (A2MAC)	Immunoglobulin G Subclass 2 (IGG2)
β₂-Microglobulin (B2MIC, B2MU**)	Immunoglobulin G Subclass 3 (IGG3)
C3 Complement (C3)	Immunoglobulin G Subclass 4 (IGG4)
C4 Complement (C4)	Immunoglobulin M (IGM)
Ceruloplasmin (CER)	Prealbumin (PREALB)
Haptoglobin (HAPT)	Retinol binding Protein (RBP)
Hemopexin (HPX)	soluble Transferrin Receptor (STFR)
Homocysteine (HCYS)	specialty Albumin (sALB*)
Immunoglobulin A (IGA)	Transferrin (TRF)
Immunoglobulin E (IGE)

For serum and plasma

** For urine

Prescription Use × (Per 21 CFR 801 Subpart D) Over-The-Counter-Use_ (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

AND/OR

Concurrence of CDRH, Office of Device Evaluation

Page 1 of

Maria M Chan

Division Sign-Off

Office of in Vitro Diagnostic Device Evaluation and Safety

K083463

Regulation Number and Section

§ 866.5630

Beta -2-microglobulin immunological test system.(a)
Identification. Abeta -2-microglobulin immunological test system is a device that consists of the reagents used to measure by immunochemical techniquesbeta -2-microglobulin (a protein molecule) in serum, urine, and other body fluids. Measurement ofbeta -2-microglobulin aids in the diagnosis of active rheumatoid arthritis and kidney disease.(b)
Classification. Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 866.9.